Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 16/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751529 | 0.92 | BCL2 (0.80) | BCL2 | |
| SCHEMBL1957357 | 0.89 | BCL2 (1.00) | BCL2 | |
| SCHEMBL1956115 | 0.87 | BCL2 (0.91) | BCL2 | |
| SCHEMBL30106002 | 0.86 | BCL2 (0.70) | BCL2 | |
| SCHEMBL1957778 | 0.86 | BCL2 (0.88) | BCL2 | |
| SCHEMBL1957673 | 0.86 | BCL2 (1.00) | BCL2 | |
| SCHEMBL21751782 | 0.86 | BCL2 (0.70) | BCL2 | |
| SCHEMBL23166129 | 0.86 | BCL2 (0.70) | BCL2 | |
| SCHEMBL23165183 | 0.86 | BCL2 (0.69) | BCL2 | |
| SCHEMBL22165782 | 0.86 | BCL2 (0.73) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240180924-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2024-06-06 | — | — | US | disclosed |
| US-11903950-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | NEWAVE PHARMACEUTICAL INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4110298-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| US-20210332065-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020041405-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885 |
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | BCL2 2/4885 |
| US-11903950-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | BCL2 2/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | BCL2 2/4885 |
| US-20240180924-A1 | BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | BCL2 3/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | BCL2 3/4885 |
| US-20210332065-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | BCL2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.